Clinical Trial Update: A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase II study of Bintrafusp Alfa (M7824) in urothelial cancer has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Bintrafusp alfa (M7824) (bintrafusp alfa)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Urothelial Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-03-22